Goat anti-Human Lipoprotein Receptor-related Protein 6, Low Density Polyclonal Antibody | anti-LRP-6 antibody

Lipoprotein Receptor-related Protein 6, Low Density (LRP6, FLJ90062, FLJ90421)

Cat. Num. AAA631298

• Reactivity: Human
• Applications: ELISA
• Purity: Affinity Purified; Purified by peptide affinity chromatography.
• Synonyms: Lipoprotein Receptor-related Protein 6; Low Density; Polyclonal Antibody; Low Density (LRP6; FLJ90062; FLJ90421); Anti -Lipoprotein Receptor-related Protein 6; anti-LRP-6 antibody

• Host: Goat
• Reactivity: Human
• Clonality: Polyclonal
• Isotype: IgG
• Specificity: Recognizes an epitope corresponding to aa 1546-1560 of human LRP6 protein. Species sequence homology: mouse, rat, canine.
• Purity/Purification: Affinity Purified; Purified by peptide affinity chromatography.
• Form/Format: Supplied as a liquid in Tris saline, pH 7.2, 0.5% BSA, 0.02% sodium azide.

• Applicable Applications for anti-LRP-6 antibody: ELISA (EL/EIA)
• Application Notes: Suitable for use in ELISA.; Dilution: Peptide ELISA Titer: 1:64,000
• Immunogen: Synthetic peptide corresponding to CMTSVATAKGYTSDL, from the internal region of human LRP6 (NP_002327.2).
• Preparation and Storage: May be stored at 4 degree C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20 degree C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Related Product Information for anti-LRP-6 antibody

This gene encodes a member of the low density lipoprotein (LDL) receptor gene family. LDL receptors are transmembrane cell surface proteins involved in receptor-mediated endocytosis of lipoprotein and protein ligands. The protein encoded by this gene functions as a receptor or, with Frizzled, a co-receptor for Wnt and thereby transmits the canonical Wnt/beta-catenin signaling cascade. Through its interaction with the Wnt/beta-catenin signaling cascade this gene plays a role in the regulation of cell differentiation, proliferation, and migration and the development of many cancer types. This protein undergoes gamma-secretase dependent RIP- (regulated intramembrane proteolysis) processing but the precise locations of the cleavage sites have not been determined.

Product Categories/Family for anti-LRP-6 antibody

Antibodies; Abs to Receptors

NCBI and Uniprot Product Information

NCBI Description

The protein encoded by this gene, low density lipoprotein-related protein 2 (LRP2) or megalin, is a multi-ligand endocytic receptor that is expressed in many different tissues but primarily in absorptive epithilial tissues such as the kidney. This glycoprotein has a large amino-terminal extracellular domain, a single transmembrane domain, and a short carboxy-terminal cytoplasmic tail. The extracellular ligand-binding-domains bind diverse macromolecules including albumin, apolipoproteins B and E, and lipoprotein lipase. The LRP2 protein is critical for the reuptake of numerous ligands, including lipoproteins, sterols, vitamin-binding proteins, and hormones. This protein also has a role in cell-signaling; extracellular ligands include parathyroid horomones and the morphogen sonic hedgehog while cytosolic ligands include MAP kinase scaffold proteins and JNK interacting proteins. Recycling of this membrane receptor is regulated by phosphorylation of its cytoplasmic domain. Mutations in this gene cause Donnai-Barrow syndrome (DBS) and facio-oculoacoustico-renal syndrome (FOAR).[provided by RefSeq, Aug 2009]

Uniprot Description

LRP2: Acts together with cubilin to mediate HDL endocytosis. May participate in regulation of parathyroid- hormone and para-thyroid-hormone-related protein release. Defects in LRP2 are the cause of Donnai-Barrow syndrome (DBS); also known as faciooculoacousticorenal syndrome (FOAR syndrome). DBS is a rare autosomal recessive disorder characterized by major malformations including agenesis of the corpus callosum, congenital diaphragmatic hernia, facial dysmorphology, ocular anomalies, sensorineural hearing loss and developmental delay. The FOAR syndrome was first described as comprising facial anomalies, ocular anomalies, sensorineural hearing loss, and proteinuria. DBS and FOAR were first described as distinct disorders but the classic distinguishing features between the 2 disorders were presence of proteinuria and absence of diaphragmatic hernia and corpus callosum anomalies in FOAR. Early reports noted that the 2 disorders shared many phenotypic features and may be identical. Although there is variability in the expression of some features (e.g. agenesis of the corpus callosum and proteinuria), DBS and FOAR are now considered to represent the same entity. Belongs to the LDLR family.

Protein type: Motility/polarity/chemotaxis; Receptor, misc.; Membrane protein, integral

Chromosomal Location of Human Ortholog: 2q31.1

Cellular Component: Golgi apparatus; endoplasmic reticulum; brush border membrane; lysosomal membrane; lysosome; endocytic vesicle; apical plasma membrane; plasma membrane; integral to membrane; coated pit; endosome; receptor complex

Molecular Function: protein binding; calcium ion binding; SH3 domain binding

Biological Process: steroid metabolic process; phototransduction, visible light; receptor-mediated endocytosis; cell proliferation; forebrain development; protein amino acid glycosylation; endocytosis; lipid metabolic process; retinoid metabolic process; vitamin D metabolic process

Disease: Donnai-barrow Syndrome